Literature DB >> 8589298

Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics.

L S Welage1, N A Mason, E J Hoffman, R M Odeh, J Dombrouski, J A Patel, R D Swartz.   

Abstract

This study was designed to evaluate the pharmacokinetics of vancomycin during hemodialysis with cellulose triacetate (CT) high-flux dialyzers and to assess the influence of membrane surface area on intradialytic clearance. In a randomized crossover fashion, the pharmacokinetics of vancomycin were evaluated during dialysis with the CT 110 and CT 190 membranes. Six hemodialysis patients received 1 g of vancomycin immediately after the completion of a dialysis session, and subsequently, blood samples were obtained over a 5-day study period. On Day 3 subjects were dialyzed with CT 110 or CT 190 membranes. The mean intradialytic clearance of vancomycin was 56.7 +/- 7.5 and 100.70 +/- 10.7 mL/min with the CT 110 and CT 190 membranes, respectively (P < 0.05). Significant rebound in vancomycin serum concentrations occurred after dialysis; this rebound appeared to be complete 3 h postdialysis. On the basis of postrebound concentrations, the apparent percent removal of vancomycin was 23.6 +/- 1.2 and 25.2 +/- 8.6% for CT 110 and CT 190 membranes, respectively (not significant). Vancomycin is significantly cleared during dialysis with cellulose triacetate membranes, and its clearance is dependent on membrane surface area. Although a small supplemental dose of vancomycin could be administered after dialysis to replace drug lost during dialysis, it may be more efficient to give a larger dose of vancomycin after several dialysis periods. The determination of vancomycin removal can be used to estimate vancomycin serum concentrations as well as dosage requirements. This in conjunction with serum concentration monitoring can be used to optimize vancomycin dosing.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589298     DOI: 10.1681/ASN.V641284

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  5 in total

1.  Predicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing Hemodialysis.

Authors:  Wasim S El Nekidy; Maher M El-Masri; Greg S Umstead; Michelle Dehoorne-Smith
Journal:  Can J Hosp Pharm       Date:  2016-10-31

2.  Application of Intrawound Vancomycin Powder during Spine Surgery in a Patient with Dialysis-Dependent Renal Failure.

Authors:  Jackson Kim; Shane M Burke; Evan Qu; Steven W Hwang; Ron I Riesenburger
Journal:  Case Rep Surg       Date:  2015-06-22

3.  Treatment of paediatric vancomycin intoxication: a case report and review of the literature.

Authors:  Mathieu Lemaire; Bairbre Connolly; Elizabeth Harvey; Christoph Licht
Journal:  NDT Plus       Date:  2010-03-17

4.  Pharmacokinetics of Vancomycin in Pediatric Patients Receiving Intermittent Hemodialysis or Hemodiafiltration.

Authors:  Erin Chung; James A Tjon; Rosaleen M Nemec; Nadya Nalli; Elizabeth A Harvey; Christoph Licht; Winnie Seto
Journal:  Kidney Int Rep       Date:  2021-02-06

Review 5.  Clinical review: use of vancomycin in haemodialysis patients.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Lucile Mercadal; Gilbert Deray
Journal:  Crit Care       Date:  2002-06-10       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.